InVivo Therapeutics (NASDAQ:NVIV) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of InVivo Therapeutics (NASDAQ:NVIV – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock. InVivo Therapeutics Price Performance InVivo Therapeutics has a 52 week low of $0.22 and a 52 week high of $2.40. […]

Related Keywords

United States , ,Invivo Therapeutics Company Profile ,Citadel Advisors ,Renaissance Technologies ,Invivo Therapeutics Holdings Corp ,Vanguard Group Inc ,Invivo Therapeutics ,Get Free Report ,Vivo Therapeutics ,Sigma Advisers ,Sigma Investments ,Vivo Therapeutics Holdings ,Neuro Spinal Scaffold ,Invivo Therapeutics Daily ,Nasdaq Nviv ,Enviv ,Medical ,Initiated Coverage ,Stocknews Com ,